RESCON–
–SUMMIT
EUROPE

17 - 18 JUNE 2025
PARIS, FRANCE

Courtyard by Marriott®
Paris Porte de Versailles

Inhalation & RESpiratory Drug Delivery | CONnected Devices

We are excited to announce the RESCON Europe 2025, set to take place in the vibrant city of Paris on June 17-18, 2025. This distinguished event is dedicated to showcasing the latest breakthroughs and technological innovations in the respiratory industry, focusing on advanced drug delivery systems and inhalation devices.

Join us as we convene industry pioneers and professionals to delve into emerging trends in Soft Mist Inhalers, Dry Powder Inhalers (DPI), and the integration of mRNA therapies for respiratory conditions. Our dynamic agenda will also address critical issues such as Sustainable Packaging Solutions, Global Regulatory Developments in the respiratory market, and the application of Artificial Intelligence (AI) in inhalation devices.

Don’t miss this unique opportunity to stay at the forefront of innovation in the respiratory sector and connect with top industry leaders.

We look forward to welcoming you to the RESCON Europe Summit 2025 in Paris!

GOLD SPONSOR

inter scientific

Excellence in Compliance. Precision in Analysis

EXHIBITION PARTNERS

IMA ACTIVE

Solid Dose Solutions

MEDIA PARTNERS

BioPharma Asia

mediaplanet

Medhealth Outlook

ON drugDELIVERY

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Mary Ann Liebert, Inc. publishers

OINDP news

Orally inhaled and nasal drug products

PHARMA network magazine

inter scientific

Excellence in Compliance. Precision in Analysis

Your Trusted Partner in Medical Device Compliance Services

At **Inter Scientific,** we partner with medical device manufacturers to navigate the complex regulatory landscape with confidence and ease.

Technical Documentation

- Expert creation and review of technical documentation.
- Analysis of General Safety and Performance Requirements.
- ISO 14971 Risk Management support for seamless compliance.
- Device classification and alignment with the State-of-the-Art standards.
- Assistance in achieving UKCA/CE Mark certification.
- Comprehensive gap analysis to enhance documentation quality.
- Analytical testing and support for verification and validation.

Auditing

- Internal audits for EU MDR compliance.
- Internal audits for UK MDR compliance.
- ISO 13485:2016 internal audits for your quality management systems.
- Gap analysis to identify areas for improvement and ensure regulatory readiness.

Expert-Led Training

Empower your team with in-depth knowledge of regulatory requirements:

- Introduction to EU MDR 2017/745: Tailored training modules for every stage of implementation.
- ISO 13485 Training: Introduction into quality management for medical devices.

Device Lifecycle

EU Services

- Device registration with EUDAMED.
- Coordination with Notified Bodies for regulatory approval.
- EU Authorised Representative services.
- Designation of a Person Responsible for Regulatory Compliance.
- Vigilance monitoring to ensure continuous compliance and safety.

UK Services

- Device registration with MHRA for UK compliance.
- Coordination with Approved Bodies for regulatory approval.
- UK Responsible Person services.
- Vigilance monitoring to ensure continuous compliance and safety.

From Documentation to Approval - We Have Got You Covered.

Comprehensive Solutions for Medical Device Success

- Proven expertise in global regulatory compliance.
- Tailored solutions to fit your unique business needs.
- Trusted by clients worldwide to deliver timely and accurate support.

Get in contact

info@inter-scientific.com
www.inter-scientific.com
+44 (0) 333 344 2272

EPM Group Executive Summary

WHO You Will Meet

80+
Attendees

20+
Speakers

RATIO

Bio/pharmaceutical manufacturing **65:35** Vendor/Solution Providers

Company Size of Attendees



- 1000+ employees
- 300-999 employees
- 50-299 employees
- less than 49 employees

Job Title of Attendees



- C-level
- SVP/VP
- Snr Director/Director
- Snr Manager/Manager

Attendee Company Annual Turnover



- 1 Billion
- $500-999Million
- $50-499 Million
- <50 Million

HOW You Will Benefit

x1000+

Relive the conference full Acess to documentation, footagesand videos.

x10+

Hours of Networking forge new professional contacts.

x20+

Case Studies Analisys

Companies attending our events

FEEDBACK

94%

RATED EVENT AS

★★★★★

Quality of the speakers

Sharing of the best practices

Spectrum of industries

Intimate atmosphere

Short-quick presentations

98%

WOULD RECOMMEND THE EVENT TO COLLEAGUES

Learn
The Key Practical Points

- **Explore the future of Metered Dose Inhalers (MDIs)** transitioning to low global warming potential (GWP) propellants.
- **Understand regulatory challenges and solutions** for sustainable propellant adoption in respiratory devices.
- **Discover advanced PBB modeling techniques** to optimize in vitro-in vivo correlations for inhaled medications.
- **Gain insights into lifecycle management and sustainability practices** from recent drug-device launches.
- **Learn innovative approaches in extractables and leachables testing** critical for pharmaceutical packaging safety.
- **Explore cutting-edge RNA nebulization methods** as potential treatments for pulmonary fibrosis.
- **Examine strategies to enhance patient adherence** through digitally supported inhalation therapies.

- **Leverage AI technology** to revolutionize pulmonary drug formulation and delivery systems.
- **Navigate key considerations in biocompatibility testing** of breathing gas pathway devices.
- **Evaluate practical cost-reduction strategies** for medical device and connected app development.
- **Identify emerging opportunities** through novel pulmonary therapeutics and connected respiratory devices.

Meet
The Speakers

Lars Asking

Head of Projects at MVIC

Carola Fuchs

Senior Director e-Health Strategies at PARI Medical Holding GmbH

Nicholas Purcell

Founder at PurcellAI

Angelo Matturro

R&D Strategic Technical Manager at Chiesi

Divya Regulagedda

Global Extractables & Leachables Manager at Chemo

Armin Braun

Division Director of the Preclinical Pharmacology and Toxicology at Fraunhofer ITEM

Felix Weiland

Head of Device Technology at Boehringer Ingelheim microParts GmbH

Jag Shur

CTO at RIGImmune Inc

Per Bäckman

CEO and Founder at Per Backman Consulting

Mary McElroy

Head, Discovery Pharmacology and Toxicology at Charles River Laboratories

Sergio Monti

Head of Strategic Planning at RxPack

Martin Kohan

Managing Toxicologist at SafeBridge Europe

Joschka T. Müller

PhD student at LMU Munich

David Edwards

Associate, Harvard University | Adjunct Professor, Johns Hopkins Medical School | Founder, Sensory Cloud Inc

DAY 1 TUESDAY, JUNE 17TH

09:00 – 09:30 RESCON Europe Registration

Session 1
Evolution and Future of pMDI and Liquid Dispensing Systems

Morning Chairperson: Felix Weiland, Head of Device Technology at Boehringer Ingelheim microParts GmbH

09:30 – 10:00 Market Evolution: Scenarios for pMDI Product Transition into Green Gas Era
Sergio Monti, Head of Strategic Planning at RxPack

10:00 – 10:30 Next Generation of pMDI with Low GWP Propellants: Challenges and Opportunities
Angelo Matturro, R&D Strategic Technical Manager at Chiesi

10:30 – 11:00 Speed Networking

11:00 – 11:30 Morning Coffee Break

Session 2
AI and Digital Innovation in Respiratory Drug Delivery

11:30 – 12:00 Respimat® Soft Mist Inhaler – Comparison to Nebulizers
Felix Weiland, Head of Device Technology at Boehringer Ingelheim microParts GmbH

12:00 – 12:30 Efficient formulation development for a dry powder inhaler
Lars Asking, Head of Projects at MVIC

12:30 – 13:00 How technology, human experience, and in-silico modelling are reshaping the future of respiratory diagnostics and treatment
Nicholas Purcell, Founder at PurcellAI

13:00 – 14:00 Lunch Break

Session 3
Regulatory, Biocompatibility & Safety in Respiratory Devices

Afternoon Chairperson: Martin Kohan, SafeBridge Europe

14:00 – 14:30 Extractables and Leachables Testing for Pharmaceutical Packaging, Products, and Medical Devices
Martin Kohan PhD, ERT, DABT, Managing Toxicologist at SafeBridge Europe

---

14:30 – 15:00 Biocompatibility of Medical Devices and Chemical Characterization
Divya Regulagedda, Global Extractables & Leachables Manager at Chemo

---

15:00 – 15:30 Afternoon Coffee-Break

15:30 – 16:30 **Panel Discussion:**
Bridging Innovation and Compliance: The Future of Respiratory Drug-Device Systems

• Regulatory alignment and biocompatibility: preparing for ISO 18562 and beyond

• Innovations in extractables/leachables and lifecycle management of combination products

• How AI is reshaping the development of sustainable respiratory devices

Panelists:
• Felix Weiland, Boehringer Ingelheim microParts GmbH
• Divya Regulagedda, Chemo
• Angelo Matturro, Chiesi
• Sergio Monti, RxPack

Moderated by: Martin Kohan, SafeBridge Europe

16:30 Closing Remarks Day 1

17:30 – 19:30 RESCON Europe Networking Reception at Courtyard Paris Porte de Versailles

DAY 2 WEDNESDAY, JUNE 18TH

08:50 - 09:00 Opening of the RESCON Europe 2nd day

Session 4
Cutting-Edge Innovations in Drug Formulations

Morning Chairperson: David Edwards, Sensory Cloud Inc

09:00 – 09:30 PBB Modelling as a Tool to Understand the IVIVC of iBCS Class I-III Inhaled Drugs
Per Bäckman, CEO and Founder at Per Backman Consulting

09:30 – 10:00 NAM-Based Prediction of Respiratory Toxicity Using Human 3D Cultures - Considerations for Liquid and Aerosol Exposures
Mary McElroy, Head, Discovery Pharmacology and Toxicology at Charles River Laboratories

10:00 – 10:30 NEED Formulation Technology: An Alternative to LNPs for Efficient Delivery of Oligonucleotides to the Respiratory Tract
Jag Shur, CTO at RIGImmune Inc

10:30 – 11:00 Coffee Break

Session 5
Innovations in Digital and Connected Inhalers

11:00 – 11:30 Digital Support for Inhalation Therapy: A Study on Therapy Adherence
Carola Fuchs, Senior Director e-Health Strategies at PARI Medical Holding GmbH

11:30 – 12:00 A First-Line Therapy for Refractory Chronic Cough
David Edwards, Associate, Harvard University | Adjunct Professor, Johns Hopkins Medical School | Founder, Sensory Cloud Inc

12:00 – 13:00 **Panel Discussion:** Reimagining Respiratory Drug Development – From Models to Molecules

- Can predictive modeling and 3D systems replace traditional preclinical approaches in respiratory toxicology and PK?
- What are the scientific and regulatory challenges in delivering RNA and oligonucleotides via the lungs?
- How do we connect emerging drug modalities with meaningful, translatable inhalation data?

Panelists:

- Jag Shur, RIGImmune Inc
- David Edwards, Sensory Cloud Inc
- Per Bäckman, Per Backman Consulting
- Mary McElroy, Charles River Laboratories

Moderated by: Armin Braun, Fraunhofer ITEM

13:00 Lunch Break

Session 6
Advances in Nebulization and RNA Therapy

Afternoon Chairperson: Armin Braun, Fraunhofer ITEM

14:00 – 14:30 Nebulization of RNA-Loaded Micelle-Embedded Polyplexes as a Potential Treatment of Idiopathic Pulmonary Fibrosis
Joschka T. Müller, PhD student at LMU Munich

14:30 – 15:00 Preclinical development of an inhalational RNAi based drug candidate against parainfluenza infection
Armin Braun, Division Director of the Preclinical Pharmacology and Toxicology at Fraunhofer ITEM

15:00 Closing Remarks & End of RESCON Europe 2025

Biographies

Lars Asking Head of Projects at MVIC

With a background in aerosol physics, Lars Asking has now been been in the pharma industry for 35 years. Lars has served big pharma companies as AstraZeneca and Novo Nordisk and also smaller companies. Lars is since 2016 at MVIC (Medicon Valley Inhalation Consortium), currently as Head of Projects. Lars currently runs several projects covering many aspects of inhaled delivery including nasal. Lars has published several papers related to mainly testing of inhalation products as well as being the author of some patents.

Carola Fuchs Senior Director e-Health Strategies at PARI Medical Holding GmbH

Carola Fuchs, PhD, leads the e-Health department at PARI and is responsible for development, lifecycle management, business development and management of all e-Health activities for the PARI Group. She joined PARI after working for Sanofi and a biotech start-up in 2006, starting her work on connected devices as a project leader at PARI Pharma. Since then, she has established digital solutions and an international network of contacts in the field of digital health. Dr Fuchs has a Master's degree in Mechanical Engineering from the Technical University of Munich, Germany, and a PhD from the Technical University of Hamburg-Harburg, Germany.

Nicholas Purcell Founder at PurcellAI

Nicholas is the founder of Purcell, a UK-based MedTech company building the future of respiratory care. Driven by personal experience and the belief that waiting months for answers is unacceptable, Purcell is pioneering an AI-powered platform to transform diagnostics and treatment into real-time, personalised, and sustainable care. Purcell BioPro+™ is being developed to provide lab-grade testing at home, fitting in the palm of your hand, while Purcell InhalerPro™ aims to redefine inhaled drug delivery with AI-driven optimisation and real-time tracking.

Angelo Matturro R&D Strategic Technical Manager at Chiesi

Angelo Matturro studied Pharmaceutical Chemistry and Technologies at the University of Salerno (Italy). After experience in Genetic spa gained in 5y with focus on development equivalent drugs working with different dosage forms in ophthalmic and inhalation therapeutic area, Angelo joined Chiesi in 2017 as CMC Analytical Scientist in R&D with focus on development drugs in inhalation field. In 2023 he successful completed the European Course of Pharmaceutical Medicine (ECPM) at University of Basel. His expertise is in inhalation field with focus on pMDI drug development. He coordinates and supports all analytical activities mainly for clinical late phase up to the market and Life Cycle Management of pharmaceutical products. Currently his role is R&D Strategic Technical Leader accountable for define the CMC strategic plan for NCEs and late-stage projects.

Divya Regulagedda Global Extractables & Leachables Manager at Chemo

Divya Regulagedda holds a Master's degree in Pharmacy in Pharmaceutical Analysis and Quality Assurance and has 12 years of experience in the field of E & L. She has hands-on experience with LC-MS/MS, LC-QTOF, GC-MS/MS, ICP-MS, and IC. Currently, she is responsible for the E & L work in Chemo Group (part of Insud Pharma) for pharmaceutical products and medical devices. The company is a generic pharmaceutical company with a portfolio that includes solids, inhalations, hormonal products, devices, and injectables. She has experience with material evaluations used in packaging and device materials, nitrosamines, and overall toxicological evaluations.

Armin Braun Division Director of the Preclinical Pharmacology and Toxicology at Fraunhofer ITEM

Prof. Dr. rer. nat. Armin Braun, is Division Director of the Preclinical Pharmacology and Toxicology of the Fraunhofer Institute for Toxicology and Experimental Medicine. His main focus is the preclinical development and evaluation of new drugs for airway and immune diseases. Both safety and efficacy testings are performed under highest quality standard including GLP. He is deputy head of the Fraunhofer GLP facility in Hannover. Partners are the major pharmaceutical and biotech companies from Europe, US and Japan. Therefore, he has extensive experience with animal models of immune mediated lung disease like asthma, COPD or lung infection. In addition, immunotoxicology is an important field of expertise and he is acting as work package lead in the IMI EU project ImSAVAR (Immune safety avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies).

Felix Weiland Head of Device Technology at Boehringer Ingelheim microParts GmbH

Felix is a pharmacist by training with a PhD in pharmacology. In 2006, he joined Boehringer Ingelheim as a trainee, focusing on launch and transfer activities of inhalative products. He took over different roles at BI microParts for development of inhalation devices as QA Head, senior project manager and lab head for design engineering. In 2010, he joined the Ger-resheimer Group as a QC head and later on quality director for large-scale manufacturing of sterile primary packaging components, i.e.RTF®- syringes and insulin cartridges. In 2015, he returned to Boehringer Ingelheim to implement structures for life cycle management of the Respimat® Plat¬form Technology, including ownership of design history files for existing products and launching the new Respimat Reusable® in Europe in 2018. Currently he is the director of Device Technology in operations.

Biographies

Jag Shur CTO at RIGImmune Inc

Jag Shur is a pioneering researcher and entrepreneur. He is currently CTO at RIGImmune Inc, a clinical stage biotech developing advanced nucleic acid treatments for respiratory medicine. Shur holds a Ph.D. in Inhaled Biopharmaceutics: Drug Delivery to the Cystic Fibrosis Airways from the University of Portsmouth and has led significant advancements in drug delivery systems throughout his career. Before completing his Ph.D., Shur was the leader of the advanced drug formulation design team at Profile Drug Delivery, where he spearheaded the development of innovative liquid-dose inhaler formulations. Subsequently, at GlaxoSmithKline, Shur excelled as the lead formulator and analytical scientist for dry powder inhalers and pressurized metered dose inhalers.

Per Bäckman CEO and Founder at Per Backman Consulting

Dr Per Bäckman has 30 years of experience in developing inhaled medicines and has published +35 papers. Since 2010, Dr Bäckman has been mainly focused on the development and application of physiology-based biopharmaceutical models to enable understanding of the in vitro-in vivo relationships governing the exposure of inhaled medicines. Dr Bäckman is the founder and owner of Per Backman Consulting and provide services to Clients either through his own company or through the co-owned Medicon Valley Inhalation Consortium (MVIC). Dr Bäckman is also the co-chair of the PQRI working group to develop and establish the Biopharmaceutical Classification System for inhaled medicines (iBCS).

Mary McElroy Head, Discovery Pharmacology and Toxicology at Charles River Laboratories

Mary McElroy has worked in lung discovery and safety assessment for over 25 years. At Charles River, Mary combines her current role as Head of the Discovery Pharmacology and Toxicology with previous roles as an inhalation toxicologist and academic group leader in respiratory biology. Mary received her PhD from the University of Southampton and performed her postdoctoral work at the University of California at San Francisco. She has an MSc in Toxicology, an MBA from the Open University, and is a European Registered Toxicologist.

Sergio Monti Head of Strategic Planning at RxPack

Sergio Monti has over two decades of international experience in the pharmaceutical manufacturing and aerosol packaging industries. He is currently responsible for Strategic Planning at RxPack Srl, a global leader in aerosol valves and mechanical pumps for the pharmaceutical sector, where he previously served as Head of Operations. In these roles, he has spearheaded the company's expansion, guided product portfolio rationalization, and led major initiatives in energy efficiency and sustainability reporting.

Martin Kohan Managing Toxicologist at SafeBridge Europe

BSc and MSc in Chemistry and Biochemistry from the National University of La Plata, Argentina. MSc in Pharmacology and PhD in Medical Sciences from the Hebrew University of Jerusalem, Israel. Over 20 years of experience in Pharmacology and Toxicology, including more than 14 years of industry experience in Toxicology conducting and managing over 1000 hazard/risk assessments, including calculation of exposure limits and/or determination of exposure bands for drug substances and isolated intermediates and quality deviations (impurities and extractables & leachables) for Teva (2010 – 2018), AstraZeneca (2018 – 2022), and SafeBridge (2022 – present).

Joschka T. Müller PhD student at LMU Munich

Joschka T. Müller is a licensed pharmacist in Germany since 2022 and a fourth-year PhD candidate at LMU Munich. His research in Prof. Dr. Olivia Merkel's lab focuses on developing siRNA polyplex therapies targeting human betacoronaviruses, addressing challenges in pulmonary delivery. To improve translational relevance, he uses advanced 3D models like Air-Liquid Interface (ALI) cultures and Precision-Cut Lung Slices (PCLS), enhancing predictive accuracy while adhering to 3R principles for ethical preclinical research.

David Edwards Associate, Harvard University | Adjunct Professor, Johns Hopkins Medical School | Founder, Sensory Cloud Inc

David Edwards is a scientist, inventor and writer. The founder and inventor of FEND, 2020 Time Magazine Best Invention of the Year, a new daily rite for cleansing the lungs, David's inventions and startups have led to FDA-approved products on the market such as Inbrijia (inhaled L Dopa for Parkinson's). David was Professor of the Practice of Bioengineering at Harvard University in the School of Engineering & Applied Sciences from 2001 to 2019, and transitioned to Associate at the start of the pandemic to help pioneer the science and global clinical trial program of airway hydration. At Harvard, David's innovation learning programs have helped pioneer new ways of thinking about the translation of high-impact ideas as captured in his most recent book Creating Things That Matter (Holt 2018), Nautilus Book Award winner in 2018 in the category of creativity.


COURTYARD
PARISSY

Courtyard by Marriott® - Paris

RESCON Europe 2025 will take place at the modern and stylish Courtyard Paris Porte de Versailles****. Ideally located just steps from Paris Expo Porte de Versailles, the venue offers an inspiring atmosphere with contemporary design, spacious meeting areas, and cutting-edge facilities. Guests will enjoy comfortable accommodations, a rooftop bar with panoramic city views, and seamless transport connections to central Paris. Whether you're here to exchange insights or expand your network, this venue provides the perfect backdrop for meaningful conversations and innovation in respiratory and connected device technologies.

5 Rue Ernest Renan, 92130
Issy-les-Moulineaux, France